詳細検索

詳細検索

お問い合わせ

Global Biologics Contract Manufacturing Market Outlook, InDepth Analysis & Forecast to 2032

Global Biologics Contract Manufacturing Market Outlook, InDepth Analysis & Forecast to 2032


生物製剤受託製造の世界市場 2026-2032年

The global Biologics Contract Manufacturing market is projected to grow from US$ 89453 million in 2025 to US$ 173452 million by 2032, at a CAGR of 9.9% (2026-2032), driven by critical product segme... もっと見る

 

 

出版社
QYResearch
QYリサーチ
出版年月
2026年11月15日
電子版価格
US$4,900
シングルユーザライセンス
ライセンス・価格情報/注文方法はこちら
納期
5-7営業日
言語
英語

英語原文をAIを使って翻訳しています。


 

お問い合わせ

お問合せ種類/内容 *

補足が有ればご記入ください
貴社名*
ご担当者名 * 姓 名
メールアドレス *

ページTOPに戻る



図表リスト

List of Tables
Table 1. Global Biologics Contract Manufacturing Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Biologics Contract Manufacturing Market Size Growth Rate by Manufacturing Service Type 按, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Biologics Contract Manufacturing Market Size Growth Rate by Development and Commercialization Stage, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Biologics Contract Manufacturing Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Biologics Contract Manufacturing Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Biologics Contract Manufacturing Revenue by Region (US$ Million), 2021-2026
Table 7. Global Biologics Contract Manufacturing Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Biologics Contract Manufacturing Revenue by Players (US$ Million), 2021-2026
Table 10. Global Biologics Contract Manufacturing Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Biologics Contract Manufacturing Revenue, 2025
Table 13. Global Biologics Contract Manufacturing Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Biologics Contract Manufacturing Companies Headquarters
Table 15. Global Biologics Contract Manufacturing Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Biologics Contract Manufacturing Revenue by Type (US$ Million), 2021-2026
Table 19. Global Biologics Contract Manufacturing Revenue by Type (US$ Million), 2027-2032
Table 20. Global Biologics Contract Manufacturing Revenue by Manufacturing Service Type 按 (US$ Million), 2021-2026
Table 21. Global Biologics Contract Manufacturing Revenue by Manufacturing Service Type 按 (US$ Million), 2027-2032
Table 22. Global Biologics Contract Manufacturing Revenue by Development and Commercialization Stage (US$ Million), 2021-2026
Table 23. Global Biologics Contract Manufacturing Revenue by Development and Commercialization Stage (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Biologics Contract Manufacturing Revenue by Application (US$ Million), 2021-2026
Table 26. Global Biologics Contract Manufacturing Revenue by Application (US$ Million), 2027-2032
Table 27. Biologics Contract Manufacturing High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America Biologics Contract Manufacturing Growth Accelerators and Market Barriers
Table 31. North America Biologics Contract Manufacturing Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Biologics Contract Manufacturing Growth Accelerators and Market Barriers
Table 33. Europe Biologics Contract Manufacturing Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Biologics Contract Manufacturing Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Biologics Contract Manufacturing Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Biologics Contract Manufacturing Investment Opportunities and Key Challenges
Table 37. Central and South America Biologics Contract Manufacturing Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Biologics Contract Manufacturing Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Biologics Contract Manufacturing Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. Lonza Group AG Corporation Information
Table 41. Lonza Group AG Description and Major Businesses
Table 42. Lonza Group AG Product Features and Attributes
Table 43. Lonza Group AG Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. Lonza Group AG Revenue Proportion by Product in 2025
Table 45. Lonza Group AG Revenue Proportion by Application in 2025
Table 46. Lonza Group AG Revenue Proportion by Geographic Area in 2025
Table 47. Lonza Group AG Biologics Contract Manufacturing SWOT Analysis
Table 48. Lonza Group AG Recent Developments
Table 49. Samsung Biologics Co., Ltd. Corporation Information
Table 50. Samsung Biologics Co., Ltd. Description and Major Businesses
Table 51. Samsung Biologics Co., Ltd. Product Features and Attributes
Table 52. Samsung Biologics Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. Samsung Biologics Co., Ltd. Revenue Proportion by Product in 2025
Table 54. Samsung Biologics Co., Ltd. Revenue Proportion by Application in 2025
Table 55. Samsung Biologics Co., Ltd. Revenue Proportion by Geographic Area in 2025
Table 56. Samsung Biologics Co., Ltd. Biologics Contract Manufacturing SWOT Analysis
Table 57. Samsung Biologics Co., Ltd. Recent Developments
Table 58. WuXi Biologics (Cayman) Inc. Corporation Information
Table 59. WuXi Biologics (Cayman) Inc. Description and Major Businesses
Table 60. WuXi Biologics (Cayman) Inc. Product Features and Attributes
Table 61. WuXi Biologics (Cayman) Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. WuXi Biologics (Cayman) Inc. Revenue Proportion by Product in 2025
Table 63. WuXi Biologics (Cayman) Inc. Revenue Proportion by Application in 2025
Table 64. WuXi Biologics (Cayman) Inc. Revenue Proportion by Geographic Area in 2025
Table 65. WuXi Biologics (Cayman) Inc. Biologics Contract Manufacturing SWOT Analysis
Table 66. WuXi Biologics (Cayman) Inc. Recent Developments
Table 67. FUJIFILM Holdings Corporation Corporation Information
Table 68. FUJIFILM Holdings Corporation Description and Major Businesses
Table 69. FUJIFILM Holdings Corporation Product Features and Attributes
Table 70. FUJIFILM Holdings Corporation Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. FUJIFILM Holdings Corporation Revenue Proportion by Product in 2025
Table 72. FUJIFILM Holdings Corporation Revenue Proportion by Application in 2025
Table 73. FUJIFILM Holdings Corporation Revenue Proportion by Geographic Area in 2025
Table 74. FUJIFILM Holdings Corporation Biologics Contract Manufacturing SWOT Analysis
Table 75. FUJIFILM Holdings Corporation Recent Developments
Table 76. AGC Inc. Corporation Information
Table 77. AGC Inc. Description and Major Businesses
Table 78. AGC Inc. Product Features and Attributes
Table 79. AGC Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. AGC Inc. Revenue Proportion by Product in 2025
Table 81. AGC Inc. Revenue Proportion by Application in 2025
Table 82. AGC Inc. Revenue Proportion by Geographic Area in 2025
Table 83. AGC Inc. Biologics Contract Manufacturing SWOT Analysis
Table 84. AGC Inc. Recent Developments
Table 85. Boehringer Ingelheim International GmbH Corporation Information
Table 86. Boehringer Ingelheim International GmbH Description and Major Businesses
Table 87. Boehringer Ingelheim International GmbH Product Features and Attributes
Table 88. Boehringer Ingelheim International GmbH Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. Boehringer Ingelheim International GmbH Recent Developments
Table 90. Thermo Fisher Scientific Inc. Corporation Information
Table 91. Thermo Fisher Scientific Inc. Description and Major Businesses
Table 92. Thermo Fisher Scientific Inc. Product Features and Attributes
Table 93. Thermo Fisher Scientific Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. Thermo Fisher Scientific Inc. Recent Developments
Table 95. Novo Holdings A/S Corporation Information
Table 96. Novo Holdings A/S Description and Major Businesses
Table 97. Novo Holdings A/S Product Features and Attributes
Table 98. Novo Holdings A/S Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. Novo Holdings A/S Recent Developments
Table 100. Rentschler Biopharma SE Corporation Information
Table 101. Rentschler Biopharma SE Description and Major Businesses
Table 102. Rentschler Biopharma SE Product Features and Attributes
Table 103. Rentschler Biopharma SE Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. Rentschler Biopharma SE Recent Developments
Table 105. KBI Biopharma, Inc. Corporation Information
Table 106. KBI Biopharma, Inc. Description and Major Businesses
Table 107. KBI Biopharma, Inc. Product Features and Attributes
Table 108. KBI Biopharma, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. KBI Biopharma, Inc. Recent Developments
Table 110. Ajinomoto Co., Inc. Corporation Information
Table 111. Ajinomoto Co., Inc. Description and Major Businesses
Table 112. Ajinomoto Co., Inc. Product Features and Attributes
Table 113. Ajinomoto Co., Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. Ajinomoto Co., Inc. Recent Developments
Table 115. LOTTE BIOLOGICS Corporation Information
Table 116. LOTTE BIOLOGICS Description and Major Businesses
Table 117. LOTTE BIOLOGICS Product Features and Attributes
Table 118. LOTTE BIOLOGICS Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. LOTTE BIOLOGICS Recent Developments
Table 120. Polpharma Biologics Corporation Information
Table 121. Polpharma Biologics Description and Major Businesses
Table 122. Polpharma Biologics Product Features and Attributes
Table 123. Polpharma Biologics Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. Polpharma Biologics Recent Developments
Table 125. EirGenix, Inc. Corporation Information
Table 126. EirGenix, Inc. Description and Major Businesses
Table 127. EirGenix, Inc. Product Features and Attributes
Table 128. EirGenix, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. EirGenix, Inc. Recent Developments
Table 130. Richter-Helm BioLogics GmbH & Co. KG Corporation Information
Table 131. Richter-Helm BioLogics GmbH & Co. KG Description and Major Businesses
Table 132. Richter-Helm BioLogics GmbH & Co. KG Product Features and Attributes
Table 133. Richter-Helm BioLogics GmbH & Co. KG Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. Richter-Helm BioLogics GmbH & Co. KG Recent Developments
Table 135. Simtra BioPharma Solutions Corporation Information
Table 136. Simtra BioPharma Solutions Description and Major Businesses
Table 137. Simtra BioPharma Solutions Product Features and Attributes
Table 138. Simtra BioPharma Solutions Revenue (US$ Million) and Gross Margin (2021-2026)
Table 139. Simtra BioPharma Solutions Recent Developments
Table 140. Vetter Pharma-Fertigung GmbH & Co. KG Corporation Information
Table 141. Vetter Pharma-Fertigung GmbH & Co. KG Description and Major Businesses
Table 142. Vetter Pharma-Fertigung GmbH & Co. KG Product Features and Attributes
Table 143. Vetter Pharma-Fertigung GmbH & Co. KG Revenue (US$ Million) and Gross Margin (2021-2026)
Table 144. Vetter Pharma-Fertigung GmbH & Co. KG Recent Developments
Table 145. Piramal Pharma Limited Corporation Information
Table 146. Piramal Pharma Limited Description and Major Businesses
Table 147. Piramal Pharma Limited Product Features and Attributes
Table 148. Piramal Pharma Limited Revenue (US$ Million) and Gross Margin (2021-2026)
Table 149. Piramal Pharma Limited Recent Developments
Table 150. AbbVie Inc. Corporation Information
Table 151. AbbVie Inc. Description and Major Businesses
Table 152. AbbVie Inc. Product Features and Attributes
Table 153. AbbVie Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 154. AbbVie Inc. Recent Developments
Table 155. Emergent BioSolutions Inc. Corporation Information
Table 156. Emergent BioSolutions Inc. Description and Major Businesses
Table 157. Emergent BioSolutions Inc. Product Features and Attributes
Table 158. Emergent BioSolutions Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 159. Emergent BioSolutions Inc. Recent Developments
Table 160. SK pharmteco Corporation Information
Table 161. SK pharmteco Description and Major Businesses
Table 162. SK pharmteco Product Features and Attributes
Table 163. SK pharmteco Revenue (US$ Million) and Gross Margin (2021-2026)
Table 164. SK pharmteco Recent Developments
Table 165. Oxford Biomedica plc Corporation Information
Table 166. Oxford Biomedica plc Description and Major Businesses
Table 167. Oxford Biomedica plc Product Features and Attributes
Table 168. Oxford Biomedica plc Revenue (US$ Million) and Gross Margin (2021-2026)
Table 169. Oxford Biomedica plc Recent Developments
Table 170. WuXi XDC Cayman Inc. Corporation Information
Table 171. WuXi XDC Cayman Inc. Description and Major Businesses
Table 172. WuXi XDC Cayman Inc. Product Features and Attributes
Table 173. WuXi XDC Cayman Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 174. WuXi XDC Cayman Inc. Recent Developments
Table 175. Porton Pharma Solutions Ltd. Corporation Information
Table 176. Porton Pharma Solutions Ltd. Description and Major Businesses
Table 177. Porton Pharma Solutions Ltd. Product Features and Attributes
Table 178. Porton Pharma Solutions Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 179. Porton Pharma Solutions Ltd. Recent Developments
Table 180. Asymchem Laboratories (Tianjin) Co., Ltd. Corporation Information
Table 181. Asymchem Laboratories (Tianjin) Co., Ltd. Description and Major Businesses
Table 182. Asymchem Laboratories (Tianjin) Co., Ltd. Product Features and Attributes
Table 183. Asymchem Laboratories (Tianjin) Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 184. Asymchem Laboratories (Tianjin) Co., Ltd. Recent Developments
Table 185. BioVectra Inc. Corporation Information
Table 186. BioVectra Inc. Description and Major Businesses
Table 187. BioVectra Inc. Product Features and Attributes
Table 188. BioVectra Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 189. BioVectra Inc. Recent Developments
Table 190. Bora Pharmaceuticals Co., Ltd. Corporation Information
Table 191. Bora Pharmaceuticals Co., Ltd. Description and Major Businesses
Table 192. Bora Pharmaceuticals Co., Ltd. Product Features and Attributes
Table 193. Bora Pharmaceuticals Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 194. Bora Pharmaceuticals Co., Ltd. Recent Developments
Table 195. Recipharm AB Corporation Information
Table 196. Recipharm AB Description and Major Businesses
Table 197. Recipharm AB Product Features and Attributes
Table 198. Recipharm AB Revenue (US$ Million) and Gross Margin (2021-2026)
Table 199. Recipharm AB Recent Developments
Table 200. Minaris Regenerative Medicine Corporation Information
Table 201. Minaris Regenerative Medicine Description and Major Businesses
Table 202. Minaris Regenerative Medicine Product Features and Attributes
Table 203. Minaris Regenerative Medicine Revenue (US$ Million) and Gross Margin (2021-2026)
Table 204. Minaris Regenerative Medicine Recent Developments
Table 205. Cellipont Bioservices Corporation Information
Table 206. Cellipont Bioservices Description and Major Businesses
Table 207. Cellipont Bioservices Product Features and Attributes
Table 208. Cellipont Bioservices Revenue (US$ Million) and Gross Margin (2021-2026)
Table 209. Cellipont Bioservices Recent Developments
Table 210. Andelyn Biosciences Corporation Information
Table 211. Andelyn Biosciences Description and Major Businesses
Table 212. Andelyn Biosciences Product Features and Attributes
Table 213. Andelyn Biosciences Revenue (US$ Million) and Gross Margin (2021-2026)
Table 214. Andelyn Biosciences Recent Developments
Table 215. Danaher Corporation Corporation Information
Table 216. Danaher Corporation Description and Major Businesses
Table 217. Danaher Corporation Product Features and Attributes
Table 218. Danaher Corporation Revenue (US$ Million) and Gross Margin (2021-2026)
Table 219. Danaher Corporation Recent Developments
Table 220. BioCina Corporation Information
Table 221. BioCina Description and Major Businesses
Table 222. BioCina Product Features and Attributes
Table 223. BioCina Revenue (US$ Million) and Gross Margin (2021-2026)
Table 224. BioCina Recent Developments
Table 225. Syngene International Limited Corporation Information
Table 226. Syngene International Limited Description and Major Businesses
Table 227. Syngene International Limited Product Features and Attributes
Table 228. Syngene International Limited Revenue (US$ Million) and Gross Margin (2021-2026)
Table 229. Syngene International Limited Recent Developments
Table 230. Aragen Life Sciences Corporation Information
Table 231. Aragen Life Sciences Description and Major Businesses
Table 232. Aragen Life Sciences Product Features and Attributes
Table 233. Aragen Life Sciences Revenue (US$ Million) and Gross Margin (2021-2026)
Table 234. Aragen Life Sciences Recent Developments
Table 235. MabPlex International Corporation Information
Table 236. MabPlex International Description and Major Businesses
Table 237. MabPlex International Product Features and Attributes
Table 238. MabPlex International Revenue (US$ Million) and Gross Margin (2021-2026)
Table 239. MabPlex International Recent Developments
Table 240. GenScript Biotech Corporation Corporation Information
Table 241. GenScript Biotech Corporation Description and Major Businesses
Table 242. GenScript Biotech Corporation Product Features and Attributes
Table 243. GenScript Biotech Corporation Revenue (US$ Million) and Gross Margin (2021-2026)
Table 244. GenScript Biotech Corporation Recent Developments
Table 245. Chime Biologics Corporation Information
Table 246. Chime Biologics Description and Major Businesses
Table 247. Chime Biologics Product Features and Attributes
Table 248. Chime Biologics Revenue (US$ Million) and Gross Margin (2021-2026)
Table 249. Chime Biologics Recent Developments
Table 250. Hangzhou HJB Corporation Information
Table 251. Hangzhou HJB Description and Major Businesses
Table 252. Hangzhou HJB Product Features and Attributes
Table 253. Hangzhou HJB Revenue (US$ Million) and Gross Margin (2021-2026)
Table 254. Hangzhou HJB Recent Developments
Table 255. BiBo Pharma Corporation Information
Table 256. BiBo Pharma Description and Major Businesses
Table 257. BiBo Pharma Product Features and Attributes
Table 258. BiBo Pharma Revenue (US$ Million) and Gross Margin (2021-2026)
Table 259. BiBo Pharma Recent Developments
Table 260. Technologies, Platforms and Infrastructure
Table 261. Distributors List
Table 262. Market Trends and Market Evolution
Table 263. Market Drivers and Opportunities
Table 264. Market Challenges, Risks, and Restraints
Table 265. Research Programs/Design for This Report
Table 266. Key Data Information from Secondary Sources
Table 267. Key Data Information from Primary Sources

List of Figures
Figure 1. Global Biologics Contract Manufacturing Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. Monoclonal and Multispecific Antibodies Product Picture
Figure 3. Antibody-Drug Conjugates (ADCs) Product Picture
Figure 4. Vaccines Product Picture
Figure 5. Cell Therapy Products Product Picture
Figure 6. Gene Therapy and Viral Vector Products Product Picture
Figure 7. Nucleic Acid Therapeutics Product Picture
Figure 8. Others Product Picture
Figure 9. Global Biologics Contract Manufacturing Market Size Growth Rate by Manufacturing Service Type 按, 2021 vs 2025 vs 2032 (US$ Million)
Figure 10. Drug Substance Manufacturing Product Picture
Figure 11. Drug Product Manufacturing Product Picture
Figure 12. Integrated Drug Substance and Drug Product Manufacturing Product Picture
Figure 13. Others Product Picture
Figure 14. Global Biologics Contract Manufacturing Market Size Growth Rate by Development and Commercialization Stage, 2021 vs 2025 vs 2032 (US$ Million)
Figure 15. Preclinical and IND-enabling Manufacturing Product Picture
Figure 16. Phase I Clinical Manufacturing Product Picture
Figure 17. Phase II Clinical Manufacturing Product Picture
Figure 18. Phase III Clinical Manufacturing Product Picture
Figure 19. Others Product Picture
Figure 20. Global Biologics Contract Manufacturing Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 21. Oncology
Figure 22. Immunology and Autoimmune Diseases
Figure 23. Infectious Diseases and Vaccines
Figure 24. Metabolic and Endocrine Diseases
Figure 25. Neurological Diseases
Figure 26. Others
Figure 27. Biologics Contract Manufacturing Report Years Considered
Figure 28. Global Biologics Contract Manufacturing Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 29. Global Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 30. Global Biologics Contract Manufacturing Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 31. Global Biologics Contract Manufacturing Revenue-Based Market Share by Region (2021-2032)
Figure 32. Global Biologics Contract Manufacturing Revenue-Based Market Share Ranking (2025)
Figure 33. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 34. Monoclonal and Multispecific Antibodies Revenue-Based Market Share by Player in 2025
Figure 35. Antibody-Drug Conjugates (ADCs) Revenue-Based Market Share by Player in 2025
Figure 36. Vaccines Revenue-Based Market Share by Player in 2025
Figure 37. Cell Therapy Products Revenue-Based Market Share by Player in 2025
Figure 38. Gene Therapy and Viral Vector Products Revenue-Based Market Share by Player in 2025
Figure 39. Nucleic Acid Therapeutics Revenue-Based Market Share by Player in 2025
Figure 40. Others Revenue-Based Market Share by Player in 2025
Figure 41. Global Biologics Contract Manufacturing Revenue-Based Market Share by Type (2021-2032)
Figure 42. Global Biologics Contract Manufacturing Revenue-Based Market Share by Manufacturing Service Type 按 (2021-2032)
Figure 43. Global Biologics Contract Manufacturing Revenue-Based Market Share by Development and Commercialization Stage (2021-2032)
Figure 44. Global Biologics Contract Manufacturing Revenue-Based Market Share by Application (2021-2032)
Figure 45. North America Biologics Contract Manufacturing Revenue YoY (US$ Million), 2021-2032
Figure 46. North America Top 5 Players Biologics Contract Manufacturing Revenue (US$ Million) in 2025
Figure 47. North America Biologics Contract Manufacturing Revenue (US$ Million) by Application (2021-2032)
Figure 48. US Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 49. Canada Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 50. Mexico Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 51. Europe Biologics Contract Manufacturing Revenue YoY (US$ Million), 2021-2032
Figure 52. Europe Top 5 Players Biologics Contract Manufacturing Revenue (US$ Million) in 2025
Figure 53. Europe Biologics Contract Manufacturing Revenue (US$ Million) by Application (2021-2032)
Figure 54. Germany Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 55. France Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 56. U.K. Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 57. Italy Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 58. Russia Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 59. Asia-Pacific Biologics Contract Manufacturing Revenue YoY (US$ Million), 2021-2032
Figure 60. Asia-Pacific Top 8 Players Biologics Contract Manufacturing Revenue (US$ Million) in 2025
Figure 61. Asia-Pacific Biologics Contract Manufacturing Revenue (US$ Million) by Application (2021-2032)
Figure 62. Indonesia Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 63. Japan Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 64. South Korea Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 65. Australia Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 66. India Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 67. Indonesia Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 68. Vietnam Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 69. Malaysia Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 70. Philippines Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 71. Singapore Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 72. Central and South America Biologics Contract Manufacturing Revenue YoY (US$ Million), 2021-2032
Figure 73. Central and South America Top 5 Players Biologics Contract Manufacturing Revenue (US$ Million) in 2025
Figure 74. Central and South America Biologics Contract Manufacturing Revenue (US$ Million) by Application (2021-2032)
Figure 75. Brazil Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 76. Argentina Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 77. Middle East and Africa Biologics Contract Manufacturing Revenue YoY (US$ Million), 2021-2032
Figure 78. Middle East and Africa Top 5 Players Biologics Contract Manufacturing Revenue (US$ Million) in 2025
Figure 79. Middle East and Africa Biologics Contract Manufacturing Revenue (US$ Million) by Application (2021-2032)
Figure 80. GCC Countries Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 81. Israel Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 82. Egypt Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 83. South Africa Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 84. Biologics Contract Manufacturing Value Chain Mapping
Figure 85. Channels of Distribution (Direct Vs Distribution)
Figure 86. Bottom-up and Top-down Approaches for This Report
Figure 87. Data Triangulation
Figure 88. Key Executives Interviewed

 

ページTOPに戻る


 

Summary

The global Biologics Contract Manufacturing market is projected to grow from US$ 89453 million in 2025 to US$ 173452 million by 2032, at a CAGR of 9.9% (2026-2032), driven by critical product segments and diverse end‑use applications.

Biologics Contract Manufacturing refers to specialized outsourced manufacturing services provided by contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) for biological pharmaceutical products. The industry focuses on GMP-compliant production of biological drug substances and finished drug products under contractual agreements with pharmaceutical companies, biotechnology developers, and other drug sponsors. Major product categories include monoclonal and multispecific antibodies, recombinant proteins, antibody-drug conjugates (ADCs), vaccines, cell therapy products, gene therapy and viral vector products, nucleic acid therapeutics, and other biologics. Core manufacturing technologies encompass mammalian cell culture, microbial fermentation, viral production, cell processing, nucleic acid manufacturing, bioconjugation, downstream purification, aseptic formulation, and fill-finish operations. Manufacturing services extend from preclinical and IND-enabling production through Phase I–III clinical manufacturing to commercial pharmaceutical supply. Important operational parameters include bioreactor capacity, production yield, process consistency, critical quality attributes, batch release performance, sterility assurance, and regulatory compliance. Biologics Contract Manufacturing supports drug development and commercialization across oncology, immunology, infectious diseases, metabolic and endocrine disorders, genetic diseases, and other therapeutic areas, providing pharmaceutical sponsors with specialized manufacturing infrastructure, technical expertise, and reliable biological medicine supply.

Key Findings
Biologics Contract Manufacturing focuses on outsourced GMP production of biological drug substances and finished drug products
Monoclonal antibodies and recombinant proteins form an established foundation of biological contract manufacturing activities
Commercial biologics manufacturing generates recurring production demand through approved medicines and long-term supply agreements
North America, Europe, and Asia-Pacific are major regional centers for biological manufacturing and pharmaceutical outsourcing

Market Trends
The global Biologics Contract Manufacturing industry is evolving from traditional production outsourcing toward technologically specialized and integrated manufacturing partnerships covering multiple biological modalities and pharmaceutical development stages. Mammalian cell culture remains a foundational platform for antibody and recombinant protein manufacturing, while bispecific antibodies, ADCs, cell therapies, gene therapies, and nucleic acid therapeutics are introducing increasingly complex production requirements. Technology development is focused on high-productivity cell lines, intensified upstream processing, advanced purification systems, single-use bioreactors, automated quality monitoring, and digital manufacturing management. These technologies help manufacturers improve process consistency, increase productivity, and accommodate different batch sizes and production schedules. Pharmaceutical sponsors are also placing greater emphasis on manufacturing partners capable of coordinating drug substance production, formulation, sterile filling, and analytical support across the product lifecycle. This approach can reduce technology transfer complexity and strengthen continuity between clinical and commercial manufacturing. Another important trend is the growing demand for flexible manufacturing networks that combine established commercial production capacity with specialized facilities for emerging therapeutic modalities. The industry's long-term direction increasingly emphasizes manufacturing platform integration, operational transparency, product-specific technical expertise, and supply chain resilience rather than capacity expansion alone.

Market Dynamics
Drivers
The principal growth drivers of Biologics Contract Manufacturing are expanding biological drug development pipelines, increasing manufacturing complexity, and the strategic importance of outsourcing within the pharmaceutical industry. Biological medicines require specialized facilities, validated production processes, highly trained personnel, and comprehensive quality management systems, creating substantial financial and technical barriers to establishing independent manufacturing operations. Outsourcing enables biotechnology developers to access established GMP capabilities while reducing upfront capital requirements and adjusting production commitments to clinical development progress. Large pharmaceutical companies also engage external manufacturers to supplement internal capacity, accelerate product launches, diversify manufacturing networks, and improve operational flexibility. Continued innovation in oncology, immunology, genetic diseases, and advanced therapies broadens the range of products requiring specialized manufacturing support. Regulatory requirements concerning manufacturing consistency, contamination prevention, product traceability, and supply reliability further strengthen demand for experienced manufacturing partners. The combination of clinical pipeline development and commercial supply requirements supports a diversified demand base across manufacturing stages.

Restraints
Biologics Contract Manufacturing is constrained by high capital requirements, complex manufacturing validation, specialized operating costs, and uncertainty surrounding customer development pipelines. Establishing GMP-compliant biologics manufacturing facilities requires substantial investment in cleanrooms, bioreactors, purification equipment, analytical laboratories, contamination control infrastructure, and supporting utilities. Operating expenses are affected by skilled personnel requirements, cell culture media, chromatography materials, single-use consumables, energy costs, and extensive quality assurance procedures. Newly installed production capacity generally requires facility qualification, customer technology transfer, process validation, and regulatory approval activities before reaching stable commercial utilization. Consequently, manufacturing expansion may involve a considerable period between capital expenditure and corresponding revenue generation. Clinical trial failures, development delays, and changes in pharmaceutical pipeline priorities can also lead to production rescheduling or contract modifications. Biological manufacturing processes are often highly product-specific, limiting the flexibility of transferring projects between facilities and increasing technical and financial costs associated with capacity reallocation.

Opportunities
Important opportunities in Biologics Contract Manufacturing are emerging from complex biological medicines, advanced therapeutic technologies, commercial production outsourcing, and geographical diversification of pharmaceutical supply chains. Increasing development activity involving bispecific and multispecific antibodies, ADCs, cell therapies, gene therapies, and nucleic acid therapeutics creates demand for specialized manufacturing technologies and integrated process capabilities. Contract manufacturers supporting projects from early clinical production through commercial supply can establish longer customer relationships and participate in successive manufacturing programs. Emerging biotechnology companies also represent an important customer group because they frequently require flexible GMP manufacturing capacity without making substantial investments in dedicated facilities. Technology-related opportunities include intensified cell culture, modular manufacturing infrastructure, automated production systems, advanced analytical platforms, and improved process monitoring. Additional opportunities arise from investment in regional manufacturing capacity across North America, Europe, and selected Asia-Pacific markets. Companies combining specialized biological manufacturing expertise, consistent regulatory compliance, efficient technology transfers, and dependable commercial supply capabilities are positioned to serve increasingly complex pharmaceutical manufacturing requirements.

Challenges
The major challenges facing Biologics Contract Manufacturing involve maintaining consistent product quality, managing capacity utilization, adapting to new therapeutic technologies, and operating across different regulatory environments. Biological production is sensitive to variations in cell culture conditions, raw material quality, process parameters, equipment performance, and contamination control. Manufacturing deviations, microbial contamination, unsuccessful validation campaigns, or product quality failures can result in batch losses, production delays, regulatory consequences, and substantial financial exposure. Transitioning from clinical to commercial manufacturing requires reliable process scale-up, reproducibility, and sustained compliance with strict quality requirements. Meanwhile, investments in emerging therapeutic platforms carry commercial uncertainty because individual drug development programs may be delayed or discontinued before reaching commercialization. Manufacturers must balance capacity expansion with customer diversification, technical specialization, and the risk of underutilized facilities. International operations introduce additional challenges associated with regulatory differences, technology transfer requirements, trade policies, and regional supply chain expectations. Maintaining experienced personnel, validated processes, transparent quality systems, and dependable customer relationships remains essential for sustainable competitiveness.

Industry Chain Analysis
The Biologics Contract Manufacturing industry chain consists of upstream bioprocessing materials and equipment suppliers, midstream contract manufacturers, and downstream pharmaceutical sponsors and therapeutic markets. Upstream participants provide cell culture media, feed supplements, chromatography resins, filtration membranes, single-use processing systems, bioreactors, analytical instruments, sterile containers, and specialized production components. The quality and availability of these inputs directly influence manufacturing productivity, process reliability, and final product consistency. Different biological modalities require distinct processing materials and manufacturing technologies, making supplier qualification, traceability, and contamination control important elements of the production system.

Midstream manufacturing represents the principal value-creation stage, encompassing cell cultivation, fermentation, harvesting, purification, bioconjugation, formulation, aseptic filling, process validation, and quality testing. Contract manufacturers generate value through qualified GMP facilities, proprietary process technologies, regulatory expertise, manufacturing efficiency, and the ability to deliver consistent product quality across multiple batches. Downstream customers include multinational pharmaceutical companies, emerging biotechnology developers, and other biological medicine sponsors serving oncology, immunology, infectious diseases, metabolic disorders, and genetic diseases. The cost structure is influenced by facility depreciation, specialized labor, raw materials, manufacturing consumables, utilities, quality assurance, and regulatory compliance. Profitability depends on production yields, capacity utilization, project maturity, contract arrangements, and the balance between clinical and commercial manufacturing activities. Long-term commercial manufacturing agreements can improve production visibility, while clinical-stage projects create opportunities to establish relationships that may develop into recurring commercial supply contracts.

Segment Insights
By biological product category, monoclonal and multispecific antibodies, together with other recombinant proteins, represent an established foundation of the Biologics Contract Manufacturing industry. These products benefit from mature mammalian cell culture platforms, established downstream purification technologies, and extensive regulatory manufacturing experience. Increasing activity involving complex antibody structures and ADCs is creating demand for specialized technologies, including advanced protein expression, bioconjugation, high-containment processing, and analytical characterization. Cell and gene therapies constitute technically differentiated segments requiring dedicated manufacturing environments, viral vector capabilities, specialized quality controls, and production models adapted to small batches or patient-specific applications. Nucleic acid therapeutics and vaccines provide further opportunities for specialized manufacturing platforms. The resulting diversity of biological products creates different operational requirements, cost structures, and technical entry barriers across the industry.

By manufacturing service type, drug substance production is a central activity covering upstream cultivation and downstream purification, while drug product manufacturing involves formulation, aseptic filling, lyophilization, and finished dosage preparation. Integrated manufacturing services coordinate these activities and can reduce technology transfer complexity. Mammalian cell culture and microbial fermentation remain important established platforms, while viral production, cellular manufacturing, nucleic acid technologies, and bioconjugation serve more specialized applications. Clinical-stage manufacturing typically emphasizes flexibility, technical support, and rapid project execution. Phase III and commercial manufacturing require more extensive process validation, batch reproducibility, regulatory readiness, and dependable production capacity. Commercial manufacturing can provide recurring demand, although revenue contribution and profitability vary according to production volumes, contractual arrangements, and facility utilization. The ability to support different biological modalities and development stages efficiently is becoming an increasingly important competitive capability.

Downstream Market Opportunities
Downstream opportunities for Biologics Contract Manufacturing are closely linked to biological drug innovation, commercialization, and increasingly diverse therapeutic applications. Oncology remains an important source of manufacturing demand through monoclonal antibodies, bispecific antibodies, ADCs, and cellular immunotherapies. Immunology and autoimmune diseases support recurring manufacturing requirements for commercial antibody and recombinant protein treatments. Infectious disease prevention and treatment generate demand for vaccines and specialized biological products, while metabolic and endocrine disorders create opportunities involving recombinant therapeutic proteins and other biological medicines. Rare and genetic diseases are particularly relevant to cell therapy, gene therapy, and viral vector manufacturing, where specialized production capabilities and stringent quality controls are essential. Customer requirements vary by pharmaceutical development stage and organizational scale. Large pharmaceutical companies generally prioritize production reliability, regulatory compliance, commercial manufacturing capacity, and long-term supply arrangements, while emerging biotechnology companies place greater emphasis on flexible production schedules, technical support, and access to specialized GMP infrastructure. These differences create opportunities for both integrated international manufacturers and specialized providers serving technically demanding therapeutic categories.

Regional Insights
North America, Europe, and Asia-Pacific represent the principal regional centers of Biologics Contract Manufacturing, supported by established pharmaceutical industries, biotechnology innovation, and specialized manufacturing infrastructure. North America benefits from a strong concentration of innovative pharmaceutical companies, biotechnology developers, and advanced therapy research organizations. The United States is an important source of outsourced manufacturing projects, particularly in oncology, antibody-based medicines, and emerging therapeutic modalities. Europe retains significant manufacturing capabilities through qualified GMP facilities, experienced technical personnel, established regulatory systems, and specialized production networks. Switzerland, Germany, and other European manufacturing locations play important roles in commercial biological production and complex contract manufacturing.

Asia-Pacific has become increasingly important in the international biological manufacturing network. China has established extensive capabilities in mammalian cell culture, antibody manufacturing, and complex biological production, supporting domestic pharmaceutical developers and international customers. South Korea has developed large-scale manufacturing infrastructure for commercial biologics, particularly monoclonal antibodies and other mammalian cell-derived products. Japan maintains expertise in advanced bioprocessing technologies and specialized pharmaceutical manufacturing. India and other emerging Asian markets offer additional opportunities as domestic biotechnology activities and investment in GMP production facilities expand. Regional competition is influenced by manufacturing economics, regulatory recognition, technical capabilities, customer relationships, and localization policies. Pharmaceutical sponsors are increasingly evaluating geographical diversification, alternative manufacturing sites, and regional supply security, creating opportunities for established global providers and qualified regional manufacturers.

Competitive Landscape Analysis
The global Biologics Contract Manufacturing industry comprises large integrated CDMOs, specialized biologics manufacturers, pharmaceutical companies offering third-party manufacturing services, and technology-focused providers serving emerging therapeutic modalities. Lonza, Samsung Biologics, WuXi Biologics, FUJIFILM Holdings through its biologics manufacturing operations, AGC through AGC Biologics, and Boehringer Ingelheim through BioXcellence are important participants with established GMP manufacturing capabilities and international customer relationships. Lonza competes through integrated biologics manufacturing, specialized process technologies, and commercial production experience. Samsung Biologics emphasizes large-scale mammalian cell culture capacity, manufacturing execution, and long-term pharmaceutical supply partnerships. WuXi Biologics combines biological development and manufacturing capabilities with a broad project portfolio extending from early development to commercial production. In 2025, WuXi Biologics reported 945 integrated projects, including 74 Phase III projects and 25 commercial manufacturing projects. The company also added 209 new integrated projects, approximately two-thirds of which involved bispecific antibodies and ADCs, reflecting growing demand for complex biological modalities.

Other established participants, including Rentschler Biopharma, KBI Biopharma, LOTTE BIOLOGICS, and specialized manufacturers of ADCs, viral vectors, and cell therapies, compete through technical capabilities, production quality, regulatory experience, and customer-specific manufacturing solutions. Industry competition increasingly emphasizes production efficiency, technology transfer performance, validated commercial capacity, regulatory compliance, and the ability to retain customer projects throughout the biological drug lifecycle. Strategic development is focused on integrated manufacturing platforms, specialized technologies, flexible production infrastructure, and geographically diversified supply networks, while long-term relationships with pharmaceutical sponsors remain an important source of competitive differentiation.

Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Biologics Contract Manufacturing market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.

Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.

Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.

Market Segmentation
By Company
Lonza Group AG
Samsung Biologics Co., Ltd.
WuXi Biologics (Cayman) Inc.
FUJIFILM Holdings Corporation
AGC Inc.
Boehringer Ingelheim International GmbH
Thermo Fisher Scientific Inc.
Novo Holdings A/S
Rentschler Biopharma SE
KBI Biopharma, Inc.
Ajinomoto Co., Inc.
LOTTE BIOLOGICS
Polpharma Biologics
EirGenix, Inc.
Richter-Helm BioLogics GmbH & Co. KG
Simtra BioPharma Solutions
Vetter Pharma-Fertigung GmbH & Co. KG
Piramal Pharma Limited
AbbVie Inc.
Emergent BioSolutions Inc.
SK pharmteco
Oxford Biomedica plc
WuXi XDC Cayman Inc.
Porton Pharma Solutions Ltd.
Asymchem Laboratories (Tianjin) Co., Ltd.
BioVectra Inc.
Bora Pharmaceuticals Co., Ltd.
Recipharm AB
Minaris Regenerative Medicine
Cellipont Bioservices
Andelyn Biosciences
Danaher Corporation
BioCina
Syngene International Limited
Aragen Life Sciences
MabPlex International
GenScript Biotech Corporation
Chime Biologics
Hangzhou HJB
BiBo Pharma

Segment by Type
Monoclonal and Multispecific Antibodies
Antibody-Drug Conjugates (ADCs)
Vaccines
Cell Therapy Products
Gene Therapy and Viral Vector Products
Nucleic Acid Therapeutics
Others
Segment by Manufacturing Service Type 按
Drug Substance Manufacturing
Drug Product Manufacturing
Integrated Drug Substance and Drug Product Manufacturing
Others

Segment by Development and Commercialization Stage
Preclinical and IND-enabling Manufacturing
Phase I Clinical Manufacturing
Phase II Clinical Manufacturing
Phase III Clinical Manufacturing
Others

Segment by Application
Oncology
Immunology and Autoimmune Diseases
Infectious Diseases and Vaccines
Metabolic and Endocrine Diseases
Neurological Diseases
Others

Segment by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA

Chapter Outline
Chapter 1: Defines the Biologics Contract Manufacturing study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.

Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:

Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).

Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.

Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).

Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).

Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る


Table of Contents

1 Study Coverage
1.1 Introduction to Biologics Contract Manufacturing: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Biologics Contract Manufacturing Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Monoclonal and Multispecific Antibodies
1.2.3 Antibody-Drug Conjugates (ADCs)
1.2.4 Vaccines
1.2.5 Cell Therapy Products
1.2.6 Gene Therapy and Viral Vector Products
1.2.7 Nucleic Acid Therapeutics
1.2.8 Others
1.3 Market Segmentation by Manufacturing Service Type 按
1.3.1 Global Biologics Contract Manufacturing Market Size by Manufacturing Service Type 按, 2021 vs 2025 vs 2032
1.3.2 Drug Substance Manufacturing
1.3.3 Drug Product Manufacturing
1.3.4 Integrated Drug Substance and Drug Product Manufacturing
1.3.5 Others
1.4 Market Segmentation by Development and Commercialization Stage
1.4.1 Global Biologics Contract Manufacturing Market Size by Development and Commercialization Stage, 2021 vs 2025 vs 2032
1.4.2 Preclinical and IND-enabling Manufacturing
1.4.3 Phase I Clinical Manufacturing
1.4.4 Phase II Clinical Manufacturing
1.4.5 Phase III Clinical Manufacturing
1.4.6 Others
1.5 Market Segmentation by Application
1.5.1 Global Biologics Contract Manufacturing Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Oncology
1.5.3 Immunology and Autoimmune Diseases
1.5.4 Infectious Diseases and Vaccines
1.5.5 Metabolic and Endocrine Diseases
1.5.6 Neurological Diseases
1.5.7 Others
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Biologics Contract Manufacturing Revenue Estimates and Forecasts (2021-2032)
2.2 Global Biologics Contract Manufacturing Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competitive Landscape
3.1 Global Biologics Contract Manufacturing Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global Biologics Contract Manufacturing Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 Monoclonal and Multispecific Antibodies: Market Share by Key Players
3.3.2 Antibody-Drug Conjugates (ADCs): Market Share by Key Players
3.3.3 Vaccines: Market Share by Key Players
3.3.4 Cell Therapy Products: Market Share by Key Players
3.3.5 Gene Therapy and Viral Vector Products: Market Share by Key Players
3.3.6 Nucleic Acid Therapeutics: Market Share by Key Players
3.3.7 Others: Market Share by Key Players
3.4 Global Biologics Contract Manufacturing Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Product Segmentation
4.1 Global Biologics Contract Manufacturing Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Global Biologics Contract Manufacturing Market by Manufacturing Service Type 按
4.2.1 Global Revenue by Manufacturing Service Type 按 (2021-2032)
4.2.2 Global Revenue-Based Market Share by Manufacturing Service Type 按 (2021-2032)
4.3 Global Biologics Contract Manufacturing Market by Development and Commercialization Stage
4.3.1 Global Revenue by Development and Commercialization Stage (2021-2032)
4.3.2 Global Revenue-Based Market Share by Development and Commercialization Stage (2021-2032)
4.4 Key Product Attributes and Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Biologics Contract Manufacturing Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.1.2 Revenue-Based Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application

6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America Biologics Contract Manufacturing Market Size by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Biologics Contract Manufacturing Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico

7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe Biologics Contract Manufacturing Market Size by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Biologics Contract Manufacturing Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia

8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific Biologics Contract Manufacturing Market Size by Application (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific Biologics Contract Manufacturing Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore

9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America Biologics Contract Manufacturing Market Size by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Biologics Contract Manufacturing Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa Biologics Contract Manufacturing Market Size by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Biologics Contract Manufacturing Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 Lonza Group AG
11.1.1 Lonza Group AG Corporation Information
11.1.2 Lonza Group AG Business Overview
11.1.3 Lonza Group AG Biologics Contract Manufacturing Product Features and Attributes
11.1.4 Lonza Group AG Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.1.5 Lonza Group AG Biologics Contract Manufacturing Revenue by Product in 2025
11.1.6 Lonza Group AG Biologics Contract Manufacturing Revenue by Application in 2025
11.1.7 Lonza Group AG Biologics Contract Manufacturing Revenue by Geographic Area in 2025
11.1.8 Lonza Group AG Biologics Contract Manufacturing SWOT Analysis
11.1.9 Lonza Group AG Recent Developments
11.2 Samsung Biologics Co., Ltd.
11.2.1 Samsung Biologics Co., Ltd. Corporation Information
11.2.2 Samsung Biologics Co., Ltd. Business Overview
11.2.3 Samsung Biologics Co., Ltd. Biologics Contract Manufacturing Product Features and Attributes
11.2.4 Samsung Biologics Co., Ltd. Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.2.5 Samsung Biologics Co., Ltd. Biologics Contract Manufacturing Revenue by Product in 2025
11.2.6 Samsung Biologics Co., Ltd. Biologics Contract Manufacturing Revenue by Application in 2025
11.2.7 Samsung Biologics Co., Ltd. Biologics Contract Manufacturing Revenue by Geographic Area in 2025
11.2.8 Samsung Biologics Co., Ltd. Biologics Contract Manufacturing SWOT Analysis
11.2.9 Samsung Biologics Co., Ltd. Recent Developments
11.3 WuXi Biologics (Cayman) Inc.
11.3.1 WuXi Biologics (Cayman) Inc. Corporation Information
11.3.2 WuXi Biologics (Cayman) Inc. Business Overview
11.3.3 WuXi Biologics (Cayman) Inc. Biologics Contract Manufacturing Product Features and Attributes
11.3.4 WuXi Biologics (Cayman) Inc. Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.3.5 WuXi Biologics (Cayman) Inc. Biologics Contract Manufacturing Revenue by Product in 2025
11.3.6 WuXi Biologics (Cayman) Inc. Biologics Contract Manufacturing Revenue by Application in 2025
11.3.7 WuXi Biologics (Cayman) Inc. Biologics Contract Manufacturing Revenue by Geographic Area in 2025
11.3.8 WuXi Biologics (Cayman) Inc. Biologics Contract Manufacturing SWOT Analysis
11.3.9 WuXi Biologics (Cayman) Inc. Recent Developments
11.4 FUJIFILM Holdings Corporation
11.4.1 FUJIFILM Holdings Corporation Corporation Information
11.4.2 FUJIFILM Holdings Corporation Business Overview
11.4.3 FUJIFILM Holdings Corporation Biologics Contract Manufacturing Product Features and Attributes
11.4.4 FUJIFILM Holdings Corporation Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.4.5 FUJIFILM Holdings Corporation Biologics Contract Manufacturing Revenue by Product in 2025
11.4.6 FUJIFILM Holdings Corporation Biologics Contract Manufacturing Revenue by Application in 2025
11.4.7 FUJIFILM Holdings Corporation Biologics Contract Manufacturing Revenue by Geographic Area in 2025
11.4.8 FUJIFILM Holdings Corporation Biologics Contract Manufacturing SWOT Analysis
11.4.9 FUJIFILM Holdings Corporation Recent Developments
11.5 AGC Inc.
11.5.1 AGC Inc. Corporation Information
11.5.2 AGC Inc. Business Overview
11.5.3 AGC Inc. Biologics Contract Manufacturing Product Features and Attributes
11.5.4 AGC Inc. Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.5.5 AGC Inc. Biologics Contract Manufacturing Revenue by Product in 2025
11.5.6 AGC Inc. Biologics Contract Manufacturing Revenue by Application in 2025
11.5.7 AGC Inc. Biologics Contract Manufacturing Revenue by Geographic Area in 2025
11.5.8 AGC Inc. Biologics Contract Manufacturing SWOT Analysis
11.5.9 AGC Inc. Recent Developments
11.6 Boehringer Ingelheim International GmbH
11.6.1 Boehringer Ingelheim International GmbH Corporation Information
11.6.2 Boehringer Ingelheim International GmbH Business Overview
11.6.3 Boehringer Ingelheim International GmbH Biologics Contract Manufacturing Product Features and Attributes
11.6.4 Boehringer Ingelheim International GmbH Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.6.5 Boehringer Ingelheim International GmbH Recent Developments
11.7 Thermo Fisher Scientific Inc.
11.7.1 Thermo Fisher Scientific Inc. Corporation Information
11.7.2 Thermo Fisher Scientific Inc. Business Overview
11.7.3 Thermo Fisher Scientific Inc. Biologics Contract Manufacturing Product Features and Attributes
11.7.4 Thermo Fisher Scientific Inc. Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.7.5 Thermo Fisher Scientific Inc. Recent Developments
11.8 Novo Holdings A/S
11.8.1 Novo Holdings A/S Corporation Information
11.8.2 Novo Holdings A/S Business Overview
11.8.3 Novo Holdings A/S Biologics Contract Manufacturing Product Features and Attributes
11.8.4 Novo Holdings A/S Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.8.5 Novo Holdings A/S Recent Developments
11.9 Rentschler Biopharma SE
11.9.1 Rentschler Biopharma SE Corporation Information
11.9.2 Rentschler Biopharma SE Business Overview
11.9.3 Rentschler Biopharma SE Biologics Contract Manufacturing Product Features and Attributes
11.9.4 Rentschler Biopharma SE Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.9.5 Rentschler Biopharma SE Recent Developments
11.10 KBI Biopharma, Inc.
11.10.1 KBI Biopharma, Inc. Corporation Information
11.10.2 KBI Biopharma, Inc. Business Overview
11.10.3 KBI Biopharma, Inc. Biologics Contract Manufacturing Product Features and Attributes
11.10.4 KBI Biopharma, Inc. Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.10.5 Company Ten Recent Developments
11.11 Ajinomoto Co., Inc.
11.11.1 Ajinomoto Co., Inc. Corporation Information
11.11.2 Ajinomoto Co., Inc. Business Overview
11.11.3 Ajinomoto Co., Inc. Biologics Contract Manufacturing Product Features and Attributes
11.11.4 Ajinomoto Co., Inc. Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.11.5 Ajinomoto Co., Inc. Recent Developments
11.12 LOTTE BIOLOGICS
11.12.1 LOTTE BIOLOGICS Corporation Information
11.12.2 LOTTE BIOLOGICS Business Overview
11.12.3 LOTTE BIOLOGICS Biologics Contract Manufacturing Product Features and Attributes
11.12.4 LOTTE BIOLOGICS Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.12.5 LOTTE BIOLOGICS Recent Developments
11.13 Polpharma Biologics
11.13.1 Polpharma Biologics Corporation Information
11.13.2 Polpharma Biologics Business Overview
11.13.3 Polpharma Biologics Biologics Contract Manufacturing Product Features and Attributes
11.13.4 Polpharma Biologics Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.13.5 Polpharma Biologics Recent Developments
11.14 EirGenix, Inc.
11.14.1 EirGenix, Inc. Corporation Information
11.14.2 EirGenix, Inc. Business Overview
11.14.3 EirGenix, Inc. Biologics Contract Manufacturing Product Features and Attributes
11.14.4 EirGenix, Inc. Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.14.5 EirGenix, Inc. Recent Developments
11.15 Richter-Helm BioLogics GmbH & Co. KG
11.15.1 Richter-Helm BioLogics GmbH & Co. KG Corporation Information
11.15.2 Richter-Helm BioLogics GmbH & Co. KG Business Overview
11.15.3 Richter-Helm BioLogics GmbH & Co. KG Biologics Contract Manufacturing Product Features and Attributes
11.15.4 Richter-Helm BioLogics GmbH & Co. KG Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.15.5 Richter-Helm BioLogics GmbH & Co. KG Recent Developments
11.16 Simtra BioPharma Solutions
11.16.1 Simtra BioPharma Solutions Corporation Information
11.16.2 Simtra BioPharma Solutions Business Overview
11.16.3 Simtra BioPharma Solutions Biologics Contract Manufacturing Product Features and Attributes
11.16.4 Simtra BioPharma Solutions Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.16.5 Simtra BioPharma Solutions Recent Developments
11.17 Vetter Pharma-Fertigung GmbH & Co. KG
11.17.1 Vetter Pharma-Fertigung GmbH & Co. KG Corporation Information
11.17.2 Vetter Pharma-Fertigung GmbH & Co. KG Business Overview
11.17.3 Vetter Pharma-Fertigung GmbH & Co. KG Biologics Contract Manufacturing Product Features and Attributes
11.17.4 Vetter Pharma-Fertigung GmbH & Co. KG Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.17.5 Vetter Pharma-Fertigung GmbH & Co. KG Recent Developments
11.18 Piramal Pharma Limited
11.18.1 Piramal Pharma Limited Corporation Information
11.18.2 Piramal Pharma Limited Business Overview
11.18.3 Piramal Pharma Limited Biologics Contract Manufacturing Product Features and Attributes
11.18.4 Piramal Pharma Limited Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.18.5 Piramal Pharma Limited Recent Developments
11.19 AbbVie Inc.
11.19.1 AbbVie Inc. Corporation Information
11.19.2 AbbVie Inc. Business Overview
11.19.3 AbbVie Inc. Biologics Contract Manufacturing Product Features and Attributes
11.19.4 AbbVie Inc. Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.19.5 AbbVie Inc. Recent Developments
11.20 Emergent BioSolutions Inc.
11.20.1 Emergent BioSolutions Inc. Corporation Information
11.20.2 Emergent BioSolutions Inc. Business Overview
11.20.3 Emergent BioSolutions Inc. Biologics Contract Manufacturing Product Features and Attributes
11.20.4 Emergent BioSolutions Inc. Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.20.5 Emergent BioSolutions Inc. Recent Developments
11.21 SK pharmteco
11.21.1 SK pharmteco Corporation Information
11.21.2 SK pharmteco Business Overview
11.21.3 SK pharmteco Biologics Contract Manufacturing Product Features and Attributes
11.21.4 SK pharmteco Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.21.5 SK pharmteco Recent Developments
11.22 Oxford Biomedica plc
11.22.1 Oxford Biomedica plc Corporation Information
11.22.2 Oxford Biomedica plc Business Overview
11.22.3 Oxford Biomedica plc Biologics Contract Manufacturing Product Features and Attributes
11.22.4 Oxford Biomedica plc Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.22.5 Oxford Biomedica plc Recent Developments
11.23 WuXi XDC Cayman Inc.
11.23.1 WuXi XDC Cayman Inc. Corporation Information
11.23.2 WuXi XDC Cayman Inc. Business Overview
11.23.3 WuXi XDC Cayman Inc. Biologics Contract Manufacturing Product Features and Attributes
11.23.4 WuXi XDC Cayman Inc. Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.23.5 WuXi XDC Cayman Inc. Recent Developments
11.24 Porton Pharma Solutions Ltd.
11.24.1 Porton Pharma Solutions Ltd. Corporation Information
11.24.2 Porton Pharma Solutions Ltd. Business Overview
11.24.3 Porton Pharma Solutions Ltd. Biologics Contract Manufacturing Product Features and Attributes
11.24.4 Porton Pharma Solutions Ltd. Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.24.5 Porton Pharma Solutions Ltd. Recent Developments
11.25 Asymchem Laboratories (Tianjin) Co., Ltd.
11.25.1 Asymchem Laboratories (Tianjin) Co., Ltd. Corporation Information
11.25.2 Asymchem Laboratories (Tianjin) Co., Ltd. Business Overview
11.25.3 Asymchem Laboratories (Tianjin) Co., Ltd. Biologics Contract Manufacturing Product Features and Attributes
11.25.4 Asymchem Laboratories (Tianjin) Co., Ltd. Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.25.5 Asymchem Laboratories (Tianjin) Co., Ltd. Recent Developments
11.26 BioVectra Inc.
11.26.1 BioVectra Inc. Corporation Information
11.26.2 BioVectra Inc. Business Overview
11.26.3 BioVectra Inc. Biologics Contract Manufacturing Product Features and Attributes
11.26.4 BioVectra Inc. Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.26.5 BioVectra Inc. Recent Developments
11.27 Bora Pharmaceuticals Co., Ltd.
11.27.1 Bora Pharmaceuticals Co., Ltd. Corporation Information
11.27.2 Bora Pharmaceuticals Co., Ltd. Business Overview
11.27.3 Bora Pharmaceuticals Co., Ltd. Biologics Contract Manufacturing Product Features and Attributes
11.27.4 Bora Pharmaceuticals Co., Ltd. Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.27.5 Bora Pharmaceuticals Co., Ltd. Recent Developments
11.28 Recipharm AB
11.28.1 Recipharm AB Corporation Information
11.28.2 Recipharm AB Business Overview
11.28.3 Recipharm AB Biologics Contract Manufacturing Product Features and Attributes
11.28.4 Recipharm AB Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.28.5 Recipharm AB Recent Developments
11.29 Minaris Regenerative Medicine
11.29.1 Minaris Regenerative Medicine Corporation Information
11.29.2 Minaris Regenerative Medicine Business Overview
11.29.3 Minaris Regenerative Medicine Biologics Contract Manufacturing Product Features and Attributes
11.29.4 Minaris Regenerative Medicine Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.29.5 Minaris Regenerative Medicine Recent Developments
11.30 Cellipont Bioservices
11.30.1 Cellipont Bioservices Corporation Information
11.30.2 Cellipont Bioservices Business Overview
11.30.3 Cellipont Bioservices Biologics Contract Manufacturing Product Features and Attributes
11.30.4 Cellipont Bioservices Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.30.5 Cellipont Bioservices Recent Developments
11.31 Andelyn Biosciences
11.31.1 Andelyn Biosciences Corporation Information
11.31.2 Andelyn Biosciences Business Overview
11.31.3 Andelyn Biosciences Biologics Contract Manufacturing Product Features and Attributes
11.31.4 Andelyn Biosciences Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.31.5 Andelyn Biosciences Recent Developments
11.32 Danaher Corporation
11.32.1 Danaher Corporation Corporation Information
11.32.2 Danaher Corporation Business Overview
11.32.3 Danaher Corporation Biologics Contract Manufacturing Product Features and Attributes
11.32.4 Danaher Corporation Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.32.5 Danaher Corporation Recent Developments
11.33 BioCina
11.33.1 BioCina Corporation Information
11.33.2 BioCina Business Overview
11.33.3 BioCina Biologics Contract Manufacturing Product Features and Attributes
11.33.4 BioCina Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.33.5 BioCina Recent Developments
11.34 Syngene International Limited
11.34.1 Syngene International Limited Corporation Information
11.34.2 Syngene International Limited Business Overview
11.34.3 Syngene International Limited Biologics Contract Manufacturing Product Features and Attributes
11.34.4 Syngene International Limited Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.34.5 Syngene International Limited Recent Developments
11.35 Aragen Life Sciences
11.35.1 Aragen Life Sciences Corporation Information
11.35.2 Aragen Life Sciences Business Overview
11.35.3 Aragen Life Sciences Biologics Contract Manufacturing Product Features and Attributes
11.35.4 Aragen Life Sciences Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.35.5 Aragen Life Sciences Recent Developments
11.36 MabPlex International
11.36.1 MabPlex International Corporation Information
11.36.2 MabPlex International Business Overview
11.36.3 MabPlex International Biologics Contract Manufacturing Product Features and Attributes
11.36.4 MabPlex International Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.36.5 MabPlex International Recent Developments
11.37 GenScript Biotech Corporation
11.37.1 GenScript Biotech Corporation Corporation Information
11.37.2 GenScript Biotech Corporation Business Overview
11.37.3 GenScript Biotech Corporation Biologics Contract Manufacturing Product Features and Attributes
11.37.4 GenScript Biotech Corporation Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.37.5 GenScript Biotech Corporation Recent Developments
11.38 Chime Biologics
11.38.1 Chime Biologics Corporation Information
11.38.2 Chime Biologics Business Overview
11.38.3 Chime Biologics Biologics Contract Manufacturing Product Features and Attributes
11.38.4 Chime Biologics Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.38.5 Chime Biologics Recent Developments
11.39 Hangzhou HJB
11.39.1 Hangzhou HJB Corporation Information
11.39.2 Hangzhou HJB Business Overview
11.39.3 Hangzhou HJB Biologics Contract Manufacturing Product Features and Attributes
11.39.4 Hangzhou HJB Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.39.5 Hangzhou HJB Recent Developments
11.40 BiBo Pharma
11.40.1 BiBo Pharma Corporation Information
11.40.2 BiBo Pharma Business Overview
11.40.3 BiBo Pharma Biologics Contract Manufacturing Product Features and Attributes
11.40.4 BiBo Pharma Biologics Contract Manufacturing Revenue and Gross Margin (2021-2026)
11.40.5 BiBo Pharma Recent Developments

12 Biologics Contract Manufacturing Value Chain and Ecosystem Analysis
12.1 Biologics Contract Manufacturing Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Biologics Contract Manufacturing Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Biologics Contract Manufacturing Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る



List of Tables/Graphs

List of Tables
Table 1. Global Biologics Contract Manufacturing Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Biologics Contract Manufacturing Market Size Growth Rate by Manufacturing Service Type 按, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Biologics Contract Manufacturing Market Size Growth Rate by Development and Commercialization Stage, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Biologics Contract Manufacturing Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Biologics Contract Manufacturing Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Biologics Contract Manufacturing Revenue by Region (US$ Million), 2021-2026
Table 7. Global Biologics Contract Manufacturing Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Biologics Contract Manufacturing Revenue by Players (US$ Million), 2021-2026
Table 10. Global Biologics Contract Manufacturing Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Biologics Contract Manufacturing Revenue, 2025
Table 13. Global Biologics Contract Manufacturing Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Biologics Contract Manufacturing Companies Headquarters
Table 15. Global Biologics Contract Manufacturing Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Biologics Contract Manufacturing Revenue by Type (US$ Million), 2021-2026
Table 19. Global Biologics Contract Manufacturing Revenue by Type (US$ Million), 2027-2032
Table 20. Global Biologics Contract Manufacturing Revenue by Manufacturing Service Type 按 (US$ Million), 2021-2026
Table 21. Global Biologics Contract Manufacturing Revenue by Manufacturing Service Type 按 (US$ Million), 2027-2032
Table 22. Global Biologics Contract Manufacturing Revenue by Development and Commercialization Stage (US$ Million), 2021-2026
Table 23. Global Biologics Contract Manufacturing Revenue by Development and Commercialization Stage (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Biologics Contract Manufacturing Revenue by Application (US$ Million), 2021-2026
Table 26. Global Biologics Contract Manufacturing Revenue by Application (US$ Million), 2027-2032
Table 27. Biologics Contract Manufacturing High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America Biologics Contract Manufacturing Growth Accelerators and Market Barriers
Table 31. North America Biologics Contract Manufacturing Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Biologics Contract Manufacturing Growth Accelerators and Market Barriers
Table 33. Europe Biologics Contract Manufacturing Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Biologics Contract Manufacturing Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Biologics Contract Manufacturing Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Biologics Contract Manufacturing Investment Opportunities and Key Challenges
Table 37. Central and South America Biologics Contract Manufacturing Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Biologics Contract Manufacturing Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Biologics Contract Manufacturing Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. Lonza Group AG Corporation Information
Table 41. Lonza Group AG Description and Major Businesses
Table 42. Lonza Group AG Product Features and Attributes
Table 43. Lonza Group AG Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. Lonza Group AG Revenue Proportion by Product in 2025
Table 45. Lonza Group AG Revenue Proportion by Application in 2025
Table 46. Lonza Group AG Revenue Proportion by Geographic Area in 2025
Table 47. Lonza Group AG Biologics Contract Manufacturing SWOT Analysis
Table 48. Lonza Group AG Recent Developments
Table 49. Samsung Biologics Co., Ltd. Corporation Information
Table 50. Samsung Biologics Co., Ltd. Description and Major Businesses
Table 51. Samsung Biologics Co., Ltd. Product Features and Attributes
Table 52. Samsung Biologics Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. Samsung Biologics Co., Ltd. Revenue Proportion by Product in 2025
Table 54. Samsung Biologics Co., Ltd. Revenue Proportion by Application in 2025
Table 55. Samsung Biologics Co., Ltd. Revenue Proportion by Geographic Area in 2025
Table 56. Samsung Biologics Co., Ltd. Biologics Contract Manufacturing SWOT Analysis
Table 57. Samsung Biologics Co., Ltd. Recent Developments
Table 58. WuXi Biologics (Cayman) Inc. Corporation Information
Table 59. WuXi Biologics (Cayman) Inc. Description and Major Businesses
Table 60. WuXi Biologics (Cayman) Inc. Product Features and Attributes
Table 61. WuXi Biologics (Cayman) Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. WuXi Biologics (Cayman) Inc. Revenue Proportion by Product in 2025
Table 63. WuXi Biologics (Cayman) Inc. Revenue Proportion by Application in 2025
Table 64. WuXi Biologics (Cayman) Inc. Revenue Proportion by Geographic Area in 2025
Table 65. WuXi Biologics (Cayman) Inc. Biologics Contract Manufacturing SWOT Analysis
Table 66. WuXi Biologics (Cayman) Inc. Recent Developments
Table 67. FUJIFILM Holdings Corporation Corporation Information
Table 68. FUJIFILM Holdings Corporation Description and Major Businesses
Table 69. FUJIFILM Holdings Corporation Product Features and Attributes
Table 70. FUJIFILM Holdings Corporation Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. FUJIFILM Holdings Corporation Revenue Proportion by Product in 2025
Table 72. FUJIFILM Holdings Corporation Revenue Proportion by Application in 2025
Table 73. FUJIFILM Holdings Corporation Revenue Proportion by Geographic Area in 2025
Table 74. FUJIFILM Holdings Corporation Biologics Contract Manufacturing SWOT Analysis
Table 75. FUJIFILM Holdings Corporation Recent Developments
Table 76. AGC Inc. Corporation Information
Table 77. AGC Inc. Description and Major Businesses
Table 78. AGC Inc. Product Features and Attributes
Table 79. AGC Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. AGC Inc. Revenue Proportion by Product in 2025
Table 81. AGC Inc. Revenue Proportion by Application in 2025
Table 82. AGC Inc. Revenue Proportion by Geographic Area in 2025
Table 83. AGC Inc. Biologics Contract Manufacturing SWOT Analysis
Table 84. AGC Inc. Recent Developments
Table 85. Boehringer Ingelheim International GmbH Corporation Information
Table 86. Boehringer Ingelheim International GmbH Description and Major Businesses
Table 87. Boehringer Ingelheim International GmbH Product Features and Attributes
Table 88. Boehringer Ingelheim International GmbH Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. Boehringer Ingelheim International GmbH Recent Developments
Table 90. Thermo Fisher Scientific Inc. Corporation Information
Table 91. Thermo Fisher Scientific Inc. Description and Major Businesses
Table 92. Thermo Fisher Scientific Inc. Product Features and Attributes
Table 93. Thermo Fisher Scientific Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. Thermo Fisher Scientific Inc. Recent Developments
Table 95. Novo Holdings A/S Corporation Information
Table 96. Novo Holdings A/S Description and Major Businesses
Table 97. Novo Holdings A/S Product Features and Attributes
Table 98. Novo Holdings A/S Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. Novo Holdings A/S Recent Developments
Table 100. Rentschler Biopharma SE Corporation Information
Table 101. Rentschler Biopharma SE Description and Major Businesses
Table 102. Rentschler Biopharma SE Product Features and Attributes
Table 103. Rentschler Biopharma SE Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. Rentschler Biopharma SE Recent Developments
Table 105. KBI Biopharma, Inc. Corporation Information
Table 106. KBI Biopharma, Inc. Description and Major Businesses
Table 107. KBI Biopharma, Inc. Product Features and Attributes
Table 108. KBI Biopharma, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. KBI Biopharma, Inc. Recent Developments
Table 110. Ajinomoto Co., Inc. Corporation Information
Table 111. Ajinomoto Co., Inc. Description and Major Businesses
Table 112. Ajinomoto Co., Inc. Product Features and Attributes
Table 113. Ajinomoto Co., Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. Ajinomoto Co., Inc. Recent Developments
Table 115. LOTTE BIOLOGICS Corporation Information
Table 116. LOTTE BIOLOGICS Description and Major Businesses
Table 117. LOTTE BIOLOGICS Product Features and Attributes
Table 118. LOTTE BIOLOGICS Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. LOTTE BIOLOGICS Recent Developments
Table 120. Polpharma Biologics Corporation Information
Table 121. Polpharma Biologics Description and Major Businesses
Table 122. Polpharma Biologics Product Features and Attributes
Table 123. Polpharma Biologics Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. Polpharma Biologics Recent Developments
Table 125. EirGenix, Inc. Corporation Information
Table 126. EirGenix, Inc. Description and Major Businesses
Table 127. EirGenix, Inc. Product Features and Attributes
Table 128. EirGenix, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. EirGenix, Inc. Recent Developments
Table 130. Richter-Helm BioLogics GmbH & Co. KG Corporation Information
Table 131. Richter-Helm BioLogics GmbH & Co. KG Description and Major Businesses
Table 132. Richter-Helm BioLogics GmbH & Co. KG Product Features and Attributes
Table 133. Richter-Helm BioLogics GmbH & Co. KG Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. Richter-Helm BioLogics GmbH & Co. KG Recent Developments
Table 135. Simtra BioPharma Solutions Corporation Information
Table 136. Simtra BioPharma Solutions Description and Major Businesses
Table 137. Simtra BioPharma Solutions Product Features and Attributes
Table 138. Simtra BioPharma Solutions Revenue (US$ Million) and Gross Margin (2021-2026)
Table 139. Simtra BioPharma Solutions Recent Developments
Table 140. Vetter Pharma-Fertigung GmbH & Co. KG Corporation Information
Table 141. Vetter Pharma-Fertigung GmbH & Co. KG Description and Major Businesses
Table 142. Vetter Pharma-Fertigung GmbH & Co. KG Product Features and Attributes
Table 143. Vetter Pharma-Fertigung GmbH & Co. KG Revenue (US$ Million) and Gross Margin (2021-2026)
Table 144. Vetter Pharma-Fertigung GmbH & Co. KG Recent Developments
Table 145. Piramal Pharma Limited Corporation Information
Table 146. Piramal Pharma Limited Description and Major Businesses
Table 147. Piramal Pharma Limited Product Features and Attributes
Table 148. Piramal Pharma Limited Revenue (US$ Million) and Gross Margin (2021-2026)
Table 149. Piramal Pharma Limited Recent Developments
Table 150. AbbVie Inc. Corporation Information
Table 151. AbbVie Inc. Description and Major Businesses
Table 152. AbbVie Inc. Product Features and Attributes
Table 153. AbbVie Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 154. AbbVie Inc. Recent Developments
Table 155. Emergent BioSolutions Inc. Corporation Information
Table 156. Emergent BioSolutions Inc. Description and Major Businesses
Table 157. Emergent BioSolutions Inc. Product Features and Attributes
Table 158. Emergent BioSolutions Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 159. Emergent BioSolutions Inc. Recent Developments
Table 160. SK pharmteco Corporation Information
Table 161. SK pharmteco Description and Major Businesses
Table 162. SK pharmteco Product Features and Attributes
Table 163. SK pharmteco Revenue (US$ Million) and Gross Margin (2021-2026)
Table 164. SK pharmteco Recent Developments
Table 165. Oxford Biomedica plc Corporation Information
Table 166. Oxford Biomedica plc Description and Major Businesses
Table 167. Oxford Biomedica plc Product Features and Attributes
Table 168. Oxford Biomedica plc Revenue (US$ Million) and Gross Margin (2021-2026)
Table 169. Oxford Biomedica plc Recent Developments
Table 170. WuXi XDC Cayman Inc. Corporation Information
Table 171. WuXi XDC Cayman Inc. Description and Major Businesses
Table 172. WuXi XDC Cayman Inc. Product Features and Attributes
Table 173. WuXi XDC Cayman Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 174. WuXi XDC Cayman Inc. Recent Developments
Table 175. Porton Pharma Solutions Ltd. Corporation Information
Table 176. Porton Pharma Solutions Ltd. Description and Major Businesses
Table 177. Porton Pharma Solutions Ltd. Product Features and Attributes
Table 178. Porton Pharma Solutions Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 179. Porton Pharma Solutions Ltd. Recent Developments
Table 180. Asymchem Laboratories (Tianjin) Co., Ltd. Corporation Information
Table 181. Asymchem Laboratories (Tianjin) Co., Ltd. Description and Major Businesses
Table 182. Asymchem Laboratories (Tianjin) Co., Ltd. Product Features and Attributes
Table 183. Asymchem Laboratories (Tianjin) Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 184. Asymchem Laboratories (Tianjin) Co., Ltd. Recent Developments
Table 185. BioVectra Inc. Corporation Information
Table 186. BioVectra Inc. Description and Major Businesses
Table 187. BioVectra Inc. Product Features and Attributes
Table 188. BioVectra Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 189. BioVectra Inc. Recent Developments
Table 190. Bora Pharmaceuticals Co., Ltd. Corporation Information
Table 191. Bora Pharmaceuticals Co., Ltd. Description and Major Businesses
Table 192. Bora Pharmaceuticals Co., Ltd. Product Features and Attributes
Table 193. Bora Pharmaceuticals Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 194. Bora Pharmaceuticals Co., Ltd. Recent Developments
Table 195. Recipharm AB Corporation Information
Table 196. Recipharm AB Description and Major Businesses
Table 197. Recipharm AB Product Features and Attributes
Table 198. Recipharm AB Revenue (US$ Million) and Gross Margin (2021-2026)
Table 199. Recipharm AB Recent Developments
Table 200. Minaris Regenerative Medicine Corporation Information
Table 201. Minaris Regenerative Medicine Description and Major Businesses
Table 202. Minaris Regenerative Medicine Product Features and Attributes
Table 203. Minaris Regenerative Medicine Revenue (US$ Million) and Gross Margin (2021-2026)
Table 204. Minaris Regenerative Medicine Recent Developments
Table 205. Cellipont Bioservices Corporation Information
Table 206. Cellipont Bioservices Description and Major Businesses
Table 207. Cellipont Bioservices Product Features and Attributes
Table 208. Cellipont Bioservices Revenue (US$ Million) and Gross Margin (2021-2026)
Table 209. Cellipont Bioservices Recent Developments
Table 210. Andelyn Biosciences Corporation Information
Table 211. Andelyn Biosciences Description and Major Businesses
Table 212. Andelyn Biosciences Product Features and Attributes
Table 213. Andelyn Biosciences Revenue (US$ Million) and Gross Margin (2021-2026)
Table 214. Andelyn Biosciences Recent Developments
Table 215. Danaher Corporation Corporation Information
Table 216. Danaher Corporation Description and Major Businesses
Table 217. Danaher Corporation Product Features and Attributes
Table 218. Danaher Corporation Revenue (US$ Million) and Gross Margin (2021-2026)
Table 219. Danaher Corporation Recent Developments
Table 220. BioCina Corporation Information
Table 221. BioCina Description and Major Businesses
Table 222. BioCina Product Features and Attributes
Table 223. BioCina Revenue (US$ Million) and Gross Margin (2021-2026)
Table 224. BioCina Recent Developments
Table 225. Syngene International Limited Corporation Information
Table 226. Syngene International Limited Description and Major Businesses
Table 227. Syngene International Limited Product Features and Attributes
Table 228. Syngene International Limited Revenue (US$ Million) and Gross Margin (2021-2026)
Table 229. Syngene International Limited Recent Developments
Table 230. Aragen Life Sciences Corporation Information
Table 231. Aragen Life Sciences Description and Major Businesses
Table 232. Aragen Life Sciences Product Features and Attributes
Table 233. Aragen Life Sciences Revenue (US$ Million) and Gross Margin (2021-2026)
Table 234. Aragen Life Sciences Recent Developments
Table 235. MabPlex International Corporation Information
Table 236. MabPlex International Description and Major Businesses
Table 237. MabPlex International Product Features and Attributes
Table 238. MabPlex International Revenue (US$ Million) and Gross Margin (2021-2026)
Table 239. MabPlex International Recent Developments
Table 240. GenScript Biotech Corporation Corporation Information
Table 241. GenScript Biotech Corporation Description and Major Businesses
Table 242. GenScript Biotech Corporation Product Features and Attributes
Table 243. GenScript Biotech Corporation Revenue (US$ Million) and Gross Margin (2021-2026)
Table 244. GenScript Biotech Corporation Recent Developments
Table 245. Chime Biologics Corporation Information
Table 246. Chime Biologics Description and Major Businesses
Table 247. Chime Biologics Product Features and Attributes
Table 248. Chime Biologics Revenue (US$ Million) and Gross Margin (2021-2026)
Table 249. Chime Biologics Recent Developments
Table 250. Hangzhou HJB Corporation Information
Table 251. Hangzhou HJB Description and Major Businesses
Table 252. Hangzhou HJB Product Features and Attributes
Table 253. Hangzhou HJB Revenue (US$ Million) and Gross Margin (2021-2026)
Table 254. Hangzhou HJB Recent Developments
Table 255. BiBo Pharma Corporation Information
Table 256. BiBo Pharma Description and Major Businesses
Table 257. BiBo Pharma Product Features and Attributes
Table 258. BiBo Pharma Revenue (US$ Million) and Gross Margin (2021-2026)
Table 259. BiBo Pharma Recent Developments
Table 260. Technologies, Platforms and Infrastructure
Table 261. Distributors List
Table 262. Market Trends and Market Evolution
Table 263. Market Drivers and Opportunities
Table 264. Market Challenges, Risks, and Restraints
Table 265. Research Programs/Design for This Report
Table 266. Key Data Information from Secondary Sources
Table 267. Key Data Information from Primary Sources

List of Figures
Figure 1. Global Biologics Contract Manufacturing Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. Monoclonal and Multispecific Antibodies Product Picture
Figure 3. Antibody-Drug Conjugates (ADCs) Product Picture
Figure 4. Vaccines Product Picture
Figure 5. Cell Therapy Products Product Picture
Figure 6. Gene Therapy and Viral Vector Products Product Picture
Figure 7. Nucleic Acid Therapeutics Product Picture
Figure 8. Others Product Picture
Figure 9. Global Biologics Contract Manufacturing Market Size Growth Rate by Manufacturing Service Type 按, 2021 vs 2025 vs 2032 (US$ Million)
Figure 10. Drug Substance Manufacturing Product Picture
Figure 11. Drug Product Manufacturing Product Picture
Figure 12. Integrated Drug Substance and Drug Product Manufacturing Product Picture
Figure 13. Others Product Picture
Figure 14. Global Biologics Contract Manufacturing Market Size Growth Rate by Development and Commercialization Stage, 2021 vs 2025 vs 2032 (US$ Million)
Figure 15. Preclinical and IND-enabling Manufacturing Product Picture
Figure 16. Phase I Clinical Manufacturing Product Picture
Figure 17. Phase II Clinical Manufacturing Product Picture
Figure 18. Phase III Clinical Manufacturing Product Picture
Figure 19. Others Product Picture
Figure 20. Global Biologics Contract Manufacturing Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 21. Oncology
Figure 22. Immunology and Autoimmune Diseases
Figure 23. Infectious Diseases and Vaccines
Figure 24. Metabolic and Endocrine Diseases
Figure 25. Neurological Diseases
Figure 26. Others
Figure 27. Biologics Contract Manufacturing Report Years Considered
Figure 28. Global Biologics Contract Manufacturing Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 29. Global Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 30. Global Biologics Contract Manufacturing Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 31. Global Biologics Contract Manufacturing Revenue-Based Market Share by Region (2021-2032)
Figure 32. Global Biologics Contract Manufacturing Revenue-Based Market Share Ranking (2025)
Figure 33. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 34. Monoclonal and Multispecific Antibodies Revenue-Based Market Share by Player in 2025
Figure 35. Antibody-Drug Conjugates (ADCs) Revenue-Based Market Share by Player in 2025
Figure 36. Vaccines Revenue-Based Market Share by Player in 2025
Figure 37. Cell Therapy Products Revenue-Based Market Share by Player in 2025
Figure 38. Gene Therapy and Viral Vector Products Revenue-Based Market Share by Player in 2025
Figure 39. Nucleic Acid Therapeutics Revenue-Based Market Share by Player in 2025
Figure 40. Others Revenue-Based Market Share by Player in 2025
Figure 41. Global Biologics Contract Manufacturing Revenue-Based Market Share by Type (2021-2032)
Figure 42. Global Biologics Contract Manufacturing Revenue-Based Market Share by Manufacturing Service Type 按 (2021-2032)
Figure 43. Global Biologics Contract Manufacturing Revenue-Based Market Share by Development and Commercialization Stage (2021-2032)
Figure 44. Global Biologics Contract Manufacturing Revenue-Based Market Share by Application (2021-2032)
Figure 45. North America Biologics Contract Manufacturing Revenue YoY (US$ Million), 2021-2032
Figure 46. North America Top 5 Players Biologics Contract Manufacturing Revenue (US$ Million) in 2025
Figure 47. North America Biologics Contract Manufacturing Revenue (US$ Million) by Application (2021-2032)
Figure 48. US Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 49. Canada Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 50. Mexico Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 51. Europe Biologics Contract Manufacturing Revenue YoY (US$ Million), 2021-2032
Figure 52. Europe Top 5 Players Biologics Contract Manufacturing Revenue (US$ Million) in 2025
Figure 53. Europe Biologics Contract Manufacturing Revenue (US$ Million) by Application (2021-2032)
Figure 54. Germany Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 55. France Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 56. U.K. Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 57. Italy Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 58. Russia Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 59. Asia-Pacific Biologics Contract Manufacturing Revenue YoY (US$ Million), 2021-2032
Figure 60. Asia-Pacific Top 8 Players Biologics Contract Manufacturing Revenue (US$ Million) in 2025
Figure 61. Asia-Pacific Biologics Contract Manufacturing Revenue (US$ Million) by Application (2021-2032)
Figure 62. Indonesia Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 63. Japan Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 64. South Korea Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 65. Australia Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 66. India Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 67. Indonesia Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 68. Vietnam Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 69. Malaysia Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 70. Philippines Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 71. Singapore Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 72. Central and South America Biologics Contract Manufacturing Revenue YoY (US$ Million), 2021-2032
Figure 73. Central and South America Top 5 Players Biologics Contract Manufacturing Revenue (US$ Million) in 2025
Figure 74. Central and South America Biologics Contract Manufacturing Revenue (US$ Million) by Application (2021-2032)
Figure 75. Brazil Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 76. Argentina Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 77. Middle East and Africa Biologics Contract Manufacturing Revenue YoY (US$ Million), 2021-2032
Figure 78. Middle East and Africa Top 5 Players Biologics Contract Manufacturing Revenue (US$ Million) in 2025
Figure 79. Middle East and Africa Biologics Contract Manufacturing Revenue (US$ Million) by Application (2021-2032)
Figure 80. GCC Countries Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 81. Israel Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 82. Egypt Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 83. South Africa Biologics Contract Manufacturing Revenue (US$ Million), 2021-2032
Figure 84. Biologics Contract Manufacturing Value Chain Mapping
Figure 85. Channels of Distribution (Direct Vs Distribution)
Figure 86. Bottom-up and Top-down Approaches for This Report
Figure 87. Data Triangulation
Figure 88. Key Executives Interviewed

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同じKEY WORD(biologics)の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


QYResearch社はどのような調査会社ですか?


QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。   QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。


詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

 

2026/11/20 10:25

160.51 円

176.53 円

212.83 円

ページTOPに戻る